Peptide Schedule
Thymosin Alpha 128 residuesSDAAVDTSSEITTKDLKEKKEVVEEAENEach bubble = one amino acid. Size = residue mass. Color = chemical class.Thymosin Alpha 1
Benefits
About Thymosin Alpha 1
Thymosin Alpha 1 (Tα1) is an immune-modulating peptide naturally produced by the thymus gland. It's the master regulator of immune function, enhancing T-cell production and maturation, boosting natural killer cell activity, and modulating dendritic cells. FDA orphan drug status for hepatitis B. Approved in over 30 countries for hepatitis and as an immune adjuvant. It balances the immune system rather than just boosting it.
Who Should Consider Thymosin Alpha 1
- Individuals with chronic hepatitis B or C seeking immune-based treatment
- Patients with weakened or suppressed immune systems (immunodeficiency)
- Cancer patients undergoing chemotherapy who need immune support
- Older adults experiencing age-related immune decline (immunosenescence)
- People with recurrent viral infections or poor vaccine response
How Thymosin Alpha 1 Works
Thymosin Alpha 1 (Tα1) is a 28-amino-acid peptide that acts as a central modulator of both innate and adaptive immunity. It binds to Toll-like receptors TLR2 and TLR9 on dendritic cells, triggering MyD88-dependent signaling cascades that upregulate MHC class I and class II expression, enhancing antigen presentation to T cells. This activation stimulates the maturation of CD4+ helper T cells and CD8+ cytotoxic T cells while simultaneously promoting natural killer (NK) cell cytotoxicity. Tα1 also activates the p38 MAPK and NF-κB pathways in immune cells, driving production of Th1-type cytokines including IL-2, IL-12, and IFN-γ while suppressing excessive Th2 responses. A distinguishing feature is its immune-balancing rather than purely stimulatory action — Tα1 upregulates regulatory T cells and modulates IDO (indoleamine 2,3-dioxygenase) expression, which helps prevent autoimmune overshoot. In the thymus, it promotes thymocyte differentiation from immature CD4−/CD8− precursors into mature T-cell subsets, partially restoring thymic output even in aged or immunocompromised individuals. At the intracellular level, Tα1 enhances oxidative killing in macrophages and neutrophils by stimulating NADPH oxidase activity, contributing to improved pathogen clearance.
What to Expect
Treatment initiation. TA1 begins activating dendritic cells and priming T-cell responses. No noticeable clinical changes yet. Injection site irritation is possible but uncommon.
Early immune activation. T-cell subsets (CD4+, CD8+) begin to increase. NK cell activity starts to rise. Some users report improved energy and reduced frequency of minor infections.
Peak immune modulation. Measurable improvements in T-cell counts and function on bloodwork. Patients with hepatitis B may see ALT normalization and viral load reduction. Improved response to vaccinations if co-administered.
Sustained immune balancing. Continued improvements in immune markers. In hepatitis B trials, HBeAg seroconversion rates increased with extended treatment. Effects persist for weeks after discontinuation due to immune memory.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 750mcg | 2x/week |
| Moderate | 1,500mcg | 2x/week |
| Aggressive | 1,500mcg | Daily |
Note: Immune modulator. FDA-orphan drug status. Enhances T-cell function. Used in hepatitis B/C treatment.
How to Inject Thymosin Alpha 1
Administer subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites between administrations. Reconstitute lyophilized powder with the provided diluent or sterile water — swirl gently, do not shake. The standard clinical dose is 1.6 mg (1600 mcg) twice weekly, based on the Zadaxin prescribing information used in hepatitis B trials. Injections are typically spaced 3-4 days apart (e.g., Monday/Thursday). Best administered in the morning. No specific food or fasting requirements.
Cycling Protocol
In hepatitis B clinical trials, Tα1 was administered at 1.6 mg subcutaneously twice weekly for 6-12 months. For general immune support, shorter courses of 8-12 weeks with a 4-week break are commonly used. Some protocols use continuous low-frequency dosing (1-2x/week) without cycling for chronic immune deficiency. No desensitization or tachyphylaxis has been documented in clinical use.
Pharmacokinetics
Source: Approximately 2 hours following subcutaneous injection, with blood levels returning to baseline within 24 hours (PMID 10027483)
Loading the interactive decay curve.
Side Effects
Very well-tolerated with decades of safety data. Mild injection site reactions. Rare: rash or flu-like symptoms.
Contraindications
- Pregnancy or breastfeeding — insufficient safety data in these populations
- Known hypersensitivity to thymosin alpha-1 or any formulation component
- Organ transplant recipients on immunosuppressive therapy — risk of graft rejection from immune activation
- Active autoimmune diseases in flare (e.g., lupus, rheumatoid arthritis) — may worsen symptoms by stimulating immune activity
- Children under 18 — not adequately studied in pediatric populations
Drug Interactions
- Immunosuppressants (cyclosporine, tacrolimus, corticosteroids) — TA1 may counteract immunosuppressive effects; monitor closely
- Interferon-alpha — commonly used in combination for hepatitis; additive immune stimulation may increase flu-like side effects
- Other immune-stimulating peptides (LL-37, KPV) — stacking may cause excessive immune activation; use with caution
- Checkpoint inhibitors (nivolumab, pembrolizumab) — theoretical risk of amplified immune responses; no formal interaction studies
Storage & Stability
Molecular Profile
Related Peptides
References
- Thymosin alpha-1 (Ann N Y Acad Sci 2007)PubMed 11381492
- Zadaxin (thymosin alpha1) for the treatment of viral hepatitis (Expert Opin Biol Ther 2005)PubMed 15992078
- Pharmacokinetics of thymosin alpha1 after subcutaneous injection of three different formulations in healthy volunteers (Int J Clin Pharmacol Ther 1998)PubMed 10027483
- Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study (J Viral Hepat 1999)PubMed 10607256
- Immune modulation with thymosin alpha 1 treatment (Vitam Horm 2016)PubMed 27450734